Nifedipine

Anal sphincter hypertonia, Proctalgia, Altitude Sickness + 12 more

Treatment

3 FDA approvals

20 Active Studies for Nifedipine

What is Nifedipine

Nifedipine

The Generic name of this drug

Treatment Summary

Nifedipine, also known as BAY a 1040, is a medication used to treat high blood pressure. It belongs to the family of drugs known as calcium channel blockers and was developed by Bayer in 1972. Nifedipine is the first generation of this type of drug and has since been followed by second and third generation versions with longer-lasting effects. The most common third-generation calcium channel blocker is amlodipine. Nifedipine was approved by the FDA in 1981.

Procardia

is the brand name

image of different drug pills on a surface

Nifedipine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Procardia

Nifedipine

1981

355

Approved as Treatment by the FDA

Nifedipine, otherwise called Procardia, is approved by the FDA for 3 uses like Angina, Stable and Failed conventional therapy .

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Failed conventional therapy

Helps manage Failed conventional therapy

Vasospastic Angina

Helps manage Vasospastic Angina

Effectiveness

How Nifedipine Affects Patients

Nifedipine helps reduce blood pressure and give the heart more oxygen. It needs to be taken three times a day, typically with a dose of 10-120mg daily. It is important to be aware of the risks associated with taking nifedipine, such as very low blood pressure, chest pain, and heart attack.

How Nifedipine works in the body

Nifedipine works by stopping calcium from entering cells in the blood vessels and heart. This reduces the pressure in the vessels and increases oxygen supply to the heart, relieving angina.

When to interrupt dosage

The proposed portion of Nifedipine is contingent upon the identified disorder, for example Achalasia, Ureteral Calculus and Hypertensive disease. The measure differs, in function of the technique of delivery (e.g. Tablet, film coated, extended release or Capsule) enumerated in the table below.

Condition

Dosage

Administration

Proctalgia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Vasospastic Angina

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Edema

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Ureteral Calculi

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Angina, Stable

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Fissure in Ano

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Failed conventional therapy

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Altitude Sickness

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Raynaud Disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive Emergency

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Anal sphincter hypertonia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Obstetric Labor, Premature

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Esophageal Achalasia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Hypertension

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Warnings

Nifedipine Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nifedipine may interact with Pulse Frequency

There are 20 known major drug interactions with Nifedipine.

Common Nifedipine Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Nifedipine.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Nifedipine.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Artemether.

Nifedipine Toxicity & Overdose Risk

The lowest toxic dose of this drug in rats has been found to be 1022mg/kg and in mice is 202mg/kg. Those who overdose may experience low blood pressure, abnormal heart rate or rhythm, and fast heartbeat. Treatment may involve monitoring vital signs, raising the patient's arms and legs, and administering medications to increase blood pressure, fluids, and calcium.

image of a doctor in a lab doing drug, clinical research

Nifedipine Novel Uses: Which Conditions Have a Clinical Trial Featuring Nifedipine?

At present, 101 active trials are exploring the potential of Nifedipine to alleviate Achalasia, Hypertensive Emergency and Anal Fissure.

Condition

Clinical Trials

Trial Phases

Pulmonary Edema

0 Actively Recruiting

Hypertensive disease

41 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

Obstetric Labor, Premature

2 Actively Recruiting

Not Applicable

Angina, Stable

0 Actively Recruiting

Esophageal Achalasia

0 Actively Recruiting

Altitude Sickness

3 Actively Recruiting

Phase 1, Phase 2, Early Phase 1, Not Applicable

Raynaud Disease

1 Actively Recruiting

Phase 4

Pulmonary Hypertension

36 Actively Recruiting

Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1

Proctalgia

0 Actively Recruiting

Hypertensive Emergency

1 Actively Recruiting

Phase 2

Fissure in Ano

0 Actively Recruiting

Vasospastic Angina

1 Actively Recruiting

Phase 2, Phase 3

Anal sphincter hypertonia

0 Actively Recruiting

Ureteral Calculi

0 Actively Recruiting

Failed conventional therapy

0 Actively Recruiting

Nifedipine Reviews: What are patients saying about Nifedipine?

5

Patient Review

11/17/2015

Nifedipine for High Blood Pressure

I switched to this treatment after 10 years of taking amlodipine, and I'm really happy with the results. My gums and legs had been swelling from the previous medication, but that's not an issue anymore.

5

Patient Review

5/1/2016

Nifedipine for High Blood Pressure

This drug has been a lifesaver for me. I have chronic kidney disease, so there are a lot of blood pressure medications I can't take. When my doctor started me on this medication, my blood pressure immediately dropped into the "safe zone." I average 100-110/65-75 with this medicine, along with a few other medicines. I haven't had any side effects while taking this medicine. I would highly recommend this medication to those who have high blood pressure!

4.7

Patient Review

8/20/2017

Nifedipine for High Blood Pressure

I've been on blood pressure medication since 2005 with no avail; my blood pressure would stay at a steady 170/100. However, when I went to see a doctor out of town, he prescribed me nifedipine and wow- after just 30mg a day, my BP lowered to 135/80! If I take 60mg a day, it gets even better to 117/71. Although there's a little bit of a headache that comes along with it, I'm willing to deal with it because finally my blood pressure is controllable. Perhaps there's also a cure for the headaches somewhere down the line.

3.7

Patient Review

1/6/2014

Nifedipine for High Blood Pressure

I didn't see the results I wanted with this medication. My blood pressure only lowered from 180 to 160, which isn't enough. It also caused headaches, depression and fatigue. I tried taking an additional 30 mg, but the headaches got worse and I started feeling nauseous.

3.3

Patient Review

4/9/2015

Nifedipine for High Blood Pressure

My daughter, who is an RN, just informed me that the symptoms I am experiencing are a severe allergic reaction to this medication. These include a severe headache, sore throat, and a rash on my torso. Be aware of these side effects and consult with your doctor if you experience them.

3

Patient Review

6/1/2022

Nifedipine for High Blood Pressure

Almost immediately after starting this medication, I began experiencing a whole host of unpleasant side effects. These include: headaches, dizziness, tingling in my limbs, fatigue, and shortness of breath. If you're someone who is sensitive to medications, I would recommend steer clear of this one.

3

Patient Review

10/12/2020

Nifedipine for High Blood Pressure

Nifedipine was lowering my blood pressure as intended, but the side effects were really bad. I felt terrible all the time, and my eyes were always irritated. I stopped taking it a few days ago and feel so much better already.

2.7

Patient Review

4/15/2015

Nifedipine for High Blood Pressure

I didn't have a good experience with this medication. It gave me headaches and made my feet swell, only slightly lowered my numbers. I'm going to ask my doctor for something else as soon as possible.

2.7

Patient Review

1/4/2014

Nifedipine for High Blood Pressure

1.7

Patient Review

3/7/2018

Nifedipine for High Blood Pressure

I got a lot of unpleasant side effects from this drug, including swelling in my legs and feet, neck pain, chest pain, and vision problems. My doctor still wanted me to take it, but I refused because the side effects were too much for me to handle.

1.7

Patient Review

6/25/2018

Nifedipine for High Blood Pressure

My blood pressure dropped significantly, which is great. However, I started experiencing a lot of negative side effects like heartburn, chest pain, and lethargy.

1.3

Patient Review

7/24/2019

Nifedipine for High Blood Pressure

I am having a bad reaction to this medication. My bones are aching terribly and I think it might be giving me diabetes. I'll update soon after I figure out which pill is causing the problem.

1

Patient Review

2/12/2019

Nifedipine for High Blood Pressure

I had a really severe reaction to this medication after only taking one dose. I was extremely hot, my blood pressure and heart rate shot up, and I had a terrible headache. When I called my doctor, they told me to double the dosage! Needless to say, I won't be taking this again.

1

Patient Review

9/20/2019

Nifedipine for High Blood Pressure

Though this medication did help to lower my blood pressure, I've been experiencing some really severe headaches. My doctor says they'll eventually go away, but in the meantime, I'm just feeling really sick and uncomfortable.

1

Patient Review

8/30/2017

Nifedipine for High Blood Pressure

I had a really bad headache and started vomiting.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nifedipine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

When should you not take nifedipine?

"Nifedipine capsules (Procardia) should not be taken immediately after a heart attack."

Answered by AI

Why is nifedipine no longer used?

"The hypertension medication nifedipine, a dihydropyridine calcium channel blocker, was once widely used but is now less so due to concerns about safety and tolerability, the introduction of new classes of hypertension medications, and data showing that other classes of medications may be more effective."

Answered by AI

What is the drug nifedipine used for?

"UK

Nifedipine is medication used to treat high blood pressure. It belongs to a class of drugs called calcium channel blockers."

Answered by AI

What are the side effects of taking nifedipine?

"Bloating or swelling in the face, arms, hands, lower legs, or feet, difficulty breathing, dizziness, fainting, a fast or irregular heartbeat, feeling hot, headaches, muscle cramps, or shaking in the legs, arms or feet."

Answered by AI

Clinical Trials for Nifedipine

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Barber and Pharmacist Coordination for High Blood Pressure

35 - 79
Male
Los Angeles, CA

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Christine Albert, MD, MPH

Image of Foothills Medical Center in Calgary, Canada.

Spinal Cord Stimulation for High Blood Pressure

18+
All Sexes
Calgary, Canada

High blood pressure, also called hypertension, raises the risk of heart disease, stroke, and kidney disease. Medications work well for many people, but some people still have blood pressure that stays too high, or they have side effects from their medications. Researchers are looking for treatments that do not involve taking more medication. Nerves help control blood pressure by changing how blood vessels tighten and how hard the heart pumps. Because of this, treatments that act on nerves may be able to lower blood pressure. Spinal cord stimulation is a treatment already used to manage long-term pain. It uses a small device, placed under the skin during a standard operation, that sends mild electrical signals to the spine. Laboratory studies suggest that stimulating the lower part of the mid-back may also lower blood pressure, but this has not been carefully studied in people who already use these devices. This study will look at whether changing the settings on a spinal cord stimulator affects blood pressure. About 11 adults who have high blood pressure and who already have a spinal cord stimulator for long-term pain. No new device will be placed, and no surgery or other invasive procedure will be done for this study. Participants attend a series of study visits. At each visit, trained staff record blood pressure and heart rate while the stimulator is turned on, turned off, and set to other settings that the person's care team has approved and that the person finds comfortable. There are rest breaks between each setting. Over successive visits, the study team works to identify the settings that best lower blood pressure. Participants can stop at any time, and their usual settings are restored at the end of each visit. The study will also look at whether this kind of testing is practical and comfortable for participants. The results will help researchers decide whether larger studies of spinal cord stimulation for blood pressure control are worth doing.

Waitlist Available
Has No Placebo

Foothills Medical Center

Aaron Phillips, PhD

Have you considered Nifedipine clinical trials?

We made a collection of clinical trials featuring Nifedipine, we think they might fit your search criteria.
Go to Trials
Image of Department of Family & Community Medicine; University of Alabama at Birmingham in Birmingham, United States.

Treatment for High Blood Pressure

18+
All Sexes
Birmingham, AL

The researchers will invite 30 patients in primary care who have high blood pressure to participate in this health program with a supportive partner of their choosing (these will be the "participant pairs"). Participant pairs will be invited to complete the Heart Care Pairs health program that will include up to six sessions each including 1) some education on a health habit like physical activity and heart healthy foods, 2) goal setting together, and 3) talk about healthy communication to support one another with heart healthy habits. The researchers will work with participants to address things that get in the way of coming for visits like offering transportation and offering telehealth visits. The researchers are seeing how this program works in real life so participants will be asked to complete as many sessions as they want to and can attend. The researchers will be interested in what participants think about the sessions, if they were satisfied with the visits, and if they would recommend the program to others in their community. The researchers will ask these questions in interviews with participants. The researchers will also ask up to 25 primary care workers about how they view the program as helpful to their work with patients with high blood pressure and whether they would refer more patients to the program in the future.

Waitlist Available
Has No Placebo

Department of Family & Community Medicine; University of Alabama at Birmingham

Image of London Health Sciences Centre (LHSC) in London, Canada.

BASIC-S Intervention for Cardiovascular Risk

18+
All Sexes
London, Canada

Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed BASIC-S (Blood Pressure, Activity, Sleep, Interaction, Consumption, and Support), a framework targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.

Waitlist Available
Has No Placebo

London Health Sciences Centre (LHSC)

Image of University of Ottawa in Ottawa, Canada.

Heat and Hypoxia for Occupational Stress

18 - 70
Male
Ottawa, Canada

Extreme heat events are becoming more frequent, intense, and prolonged, increasing the risk of heat-related illness among workers performing physically demanding work in hot environments. Occupational heat-stress guidelines use work-rest schedules to limit increases in core temperature and physiological strain, but they do not clearly define the safe maximum duration of continuous work before heat-mitigation controls should begin, known as the initial stay time. Recent work has generated initial stay time recommendations for young and older workers performing moderate-intensity work in the heat; however, these recommendations were developed under normoxic conditions. In many workplaces, heat may occur alongside additional stressors such as hypoxia, including work at altitude or in oxygen-reduced environments. Hypoxia can increase cardiovascular strain, reduce arterial oxygen saturation, and impair exercise tolerance, potentially compromising heat-stress guidance developed under normal oxygen conditions. Older workers may be especially vulnerable because of age-related reductions in thermoregulatory and cardiovascular function. It remains unclear whether hypoxia increases physiological strain during work in the heat or whether current initial stay time and recovery recommendations remain protective under combined heat and hypoxic stress. The primary objective of this study is to determine whether hypoxia increases physiological strain during moderate-intensity work in the heat in young and older males. Specifically, the study will assess whether normoxia-derived initial stay times and recovery recommendations for work at 29°C wet-bulb globe temperature (37.5°C, 35% RH) remain effective during exposure to 14% inspired oxygen, simulating approximately 3000 m altitude. Healthy young and older males will complete two simulated occupational heat exposures: heat alone and heat plus hypoxia. Participants will perform moderate-intensity treadmill work based on age-specific initial stay times, followed by prescribed work-rest cycles and seated recovery. Core temperature, cardiovascular strain, oxygen saturation, skin temperature, hydration status, perceptual responses, mood, environmental stress symptoms, and cognitive function will be assessed to determine whether hypoxia modifies responses to work in the heat. Findings will help determine whether occupational heat-stress guidance requires refinement for workers exposed to combined heat and hypoxic stress.

Recruiting
Has No Placebo

University of Ottawa

Glen P Kenny, PhD

Image of NeuroFit Lab, Ivor Wynne Centre, McMaster University in Hamilton, Canada.

Isometric Handgrip Exercise for High Blood Pressure

65+
All Sexes
Hamilton, Canada

The goal of this clinical trial is to evaluate whether a short, supervised isometric handgrip exercise program is feasible and acceptable for older adults with elevated blood pressure or hypertension. It will also explore whether this type of exercise may improve blood pressure and cognitive function. The main questions it aims to answer are: * Is this handgrip exercise program practical and acceptable for older adults to participate in within a community exercise setting? * Does participation in the program lead to changes in blood pressure and cognitive function? Researchers will compare two handgrip devices to determine whether the method of delivering the exercise influences feasibility and outcomes. Participants will: * Be randomly assigned to use one of two handgrip devices. * Complete supervised exercise sessions twice per week for 4 weeks. * Perform brief handgrip contractions at a set intensity during each session. * Complete blood pressure and cognitive assessments before and after the program.

Recruiting
Has No Placebo

NeuroFit Lab, Ivor Wynne Centre, McMaster University (+1 Sites)

Jennifer Heisz, PhD

Have you considered Nifedipine clinical trials?

We made a collection of clinical trials featuring Nifedipine, we think they might fit your search criteria.
Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

2-HOBA for Salt Sensitivity of Blood Pressure

18+
All Sexes
Nashville, TN

Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+). This trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks. This phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.

Phase 2
Waitlist Available

Vanderbilt University Medical Center

Image of UPMC Magee Womens Hospital in Pittsburgh, United States.

Mobile Health Program for High Blood Pressure After Preeclampsia

18+
Female
Pittsburgh, PA

Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.

Recruiting
Has No Placebo

UPMC Magee Womens Hospital

Malamo Countouris, MD, MS

Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Blood Pressure Monitoring for Atrial Fibrillation

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if screening for atrial fibrillation (AFib), a common irregular heart rhythm, through daily home blood pressure monitoring will decrease the time to atrial fibrillation diagnosis in older adults with hypertension. The main question it aims to answer is: \-- Does introducing screening for AFib using a blood pressure monitor with AFib detection technology decrease time to AFib diagnosis in patients with high blood pressure, compared to usual care using a conventional home blood pressure monitor with no AFib detection? Participants will participate in two phases of the study: (1) clinical trial and (2) the registry. During the 6-month clinical trial period, participants will be asked to: * Take blood pressure measurements twice daily * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take blood pressure measurements twice daily * Answer monthly mobile app-based surveys Researchers will compare standard blood pressure measurements and AFib screening blood pressure measurements to see if there is a difference in the time to AFib diagnosis and other cardiovascular events. Participants will participate in two phases of the study: (1) trial and (2) the registry. During the 6-month trial period, participants will be asked to: * Take daily blood pressure measurements * Answer short weekly mobile app-based surveys * If assigned, complete continuous heart monitoring for 2 weeks and complete 1 blood test During the 12-month registry period, participants will be asked to: * Take daily blood pressure measurements * Answer monthly mobile app-based surveys

Waitlist Available
Has No Placebo

UCSF Medical Center at Parnassus

Gregory M Marcus, MD, MAS

Omron Healthcare Co., Ltd.

Have you considered Nifedipine clinical trials?

We made a collection of clinical trials featuring Nifedipine, we think they might fit your search criteria.
Go to Trials